Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug&amp;nbsp; Effectiveness Review Project

Thaler, Kylie; Chandiramani,; Hansen, Richard A.

doi:10.2147/btt.s3579

Cited by 8 publications

(5 citation statements)

References 17 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The expected side-effects according to large studies in rheumatoid arthritis are injection site reactions and respiratory and urinary infections 7. In our series only two patients (no 2 C52Y and no 6 T50M) experienced pharyngitis and bronchopneumonia, respectively.…”

supporting

confidence: 45%

Favourable and sustained response to anakinra in tumour necrosis factor receptor-associated periodic syndrome (TRAPS) with or without AA amyloidosis

Obici

Meini

Cattalini

et al. 2010

Annals of the Rheumatic Diseases

View full text Add to dashboard Cite

supporting

confidence: 45%

Favourable and sustained response to anakinra in tumour necrosis factor receptor-associated periodic syndrome (TRAPS) with or without AA amyloidosis

Obici

Meini

Cattalini

et al. 2010

Annals of the Rheumatic Diseases

View full text Add to dashboard Cite

“…However, anti-TNF drugs are considered to be more efficacious [13]. In our patient the arthritis also deteriorated when adalimumab was switched to anakinra and decreased when switched to golimumab.…”

Section: Discussionmentioning

confidence: 68%

Failure of Anti-Interleukin-1 Therapy in Severe Hidradenitis Suppurativa: A Case Report

Zee

Prens²

2013

Dermatology

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is an inflammatory, debilitating skin disease of follicular origin, characterized by painful deep-seated, inflamed lesions in mainly the inverse areas of the body. HS is notoriously difficult to treat and especially severe disease is often resistant to therapy. New therapeutic options are therefore highly needed. Elevated levels of IL-1 have been demonstrated in HS lesions. Here we report for the first time on the sequential treatment with anakinra (an IL-1 receptor antagonist) and golimumab (a TNF-α-neutralizing antibody) of a patient with severe HS and with comorbid psoriatic arthritis. Although adalimumab and golimumab were efficacious in improving arthritis complaints, both failed in improving the severe HS of our patient. Eventually the patient underwent radical excision of the inflammatory lesions and fistulas.

show abstract

“…To identify the drugs of interest, we conducted a literature search of the biologic medications currently approved and recommended to treat RA and that were primarily reimbursed through Part D (outpatient drug benefit). 16,17 We limited the study to biologic medications because the analysis of interest centers on specialty drugs (which include biologics with high list prices). Included drugs were required to have entered the market by 2018 to allow comparison across years.…”

Section: Methodsmentioning

confidence: 99%

Assessment of Expected Out-of-Pocket Spending for Rheumatoid Arthritis Biologics Among Patients Enrolled in Medicare Part D, 2010-2019

Erath

Dusetzina

2020

JAMA Netw Open

View full text Add to dashboard Cite

IMPORTANCE The closure of the Medicare Part D coverage gap from 2010 to 2019 was intended to help decrease out-of-pocket costs for beneficiaries, especially those taking high-cost drugs. However, yearly increases in list prices and the introduction of newer and more expensive drugs may have limited savings for beneficiaries. OBJECTIVE To assess the association of closure in the Medicare Part D coverage gap with projected annual out-of-pocket costs from 2010 through 2019 for rheumatoid arthritis (RA) biologics. DESIGN, SETTING, AND PARTICIPANTS This cross-sectional analysis used data from the Medicare Formulary and Pricing Files for the first quarter (January 1 to March 31) in each calendar year from 2010 to 2019 for 17 RA biologic drug and strength combinations. EXPOSURES Medicare Part D plan design and drug price by year. MAIN OUTCOMES AND MEASURES Expected annual out-of-pocket costs for 1 year of treatment.RESULTS Among the 17 drug and strength combinations assessed, list prices increased each year for every product, with a mean increase of 160% for the 6 drugs available during the entire study period.

show abstract

Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug  Effectiveness Review Project

Cited by 8 publications

References 17 publications

Favourable and sustained response to anakinra in tumour necrosis factor receptor-associated periodic syndrome (TRAPS) with or without AA amyloidosis

Favourable and sustained response to anakinra in tumour necrosis factor receptor-associated periodic syndrome (TRAPS) with or without AA amyloidosis

Failure of Anti-Interleukin-1 Therapy in Severe Hidradenitis Suppurativa: A Case Report

Assessment of Expected Out-of-Pocket Spending for Rheumatoid Arthritis Biologics Among Patients Enrolled in Medicare Part D, 2010-2019

Contact Info

Product

Resources

About